Assets, Excluding Cash

No definition available.

Name:	prgo_AssetsExcludingCash
Namespace Prefix:	prgo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Disposal Group, Including Discontinued Operation, Consideration, Assumed R&D Milestone Payment Obligations

+ References

No definition available.

+ Details

Name:	prgo_DisposalGroupIncludingDiscontinuedOperationConsiderationAssumedRDMilestonePaymentObligations
Namespace Prefix:	prgo_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Liabilities, Excluding Debt

+ References

No definition available.

+ Details

Name:	prgo_LiabilitiesExcludingDebt
Namespace Prefix:	prgo_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of consideration received or receivable for the disposal of assets and liabilities, including discontinued operation.

+ References

No definition available.

+ Details

Name:	us-gaap_DisposalGroupIncludingDiscontinuedOperationConsideration
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

The cash inflow associated with the amount received from the sale of a portion of the company's business, for example a segment, division, branch or other business, during the period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 12
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=121586364&loc=d3e3179-108585

+ Details

Name:	us-gaap_ProceedsFromDivestitureOfBusinesses
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.

+ References

No definition available.

+ Details

Name:	us-gaap_SubsequentEventLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Details

Name:	us-gaap_StatementBusinessSegmentsAxis=prgo_RXPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsAxis=prgo_RXPharmaceuticalsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Subsequent events Subsequent Events (Details) - USD ($) $ in Millions		12 Months Ended
	Mar. 01, 2021	Dec. 31, 2020	Dec. 31, 2019	Dec. 31, 2018
Subsequent Event [Line Items]
Cash consideration in definitive agreement to sell		$ 187.8	$ 182.5	$ 5.2
RX
Subsequent Event [Line Items]
Assets, excluding cash		2,100.0
Liabilities, excluding debt		$ 600.0
RX \| Subsequent Event
Subsequent Event [Line Items]
Total consideration in definitive agreement to sell	$ 1,550.0
Cash consideration in definitive agreement to sell	1,500.0
R&D milestone payments assumed by purchaser in definitive agreement to sell	$ 50.0